The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001228370p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
2/09/2026
Date registered
Help: Date registered
7/10/2026
Date last updated
Help: Date last updated
7/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Patients with Actinic Keratosis and Intraepidermal Carcinoma: A Pilot Randomised Trial Comparing Two Concentrations of Calcipotriol in Combination with Topical 5-Fluorouracil for Lesion Clearance
Scientific title
A Pilot Randomised Participant-Blinded Split-Face Trial in Patients with Actinic Keratosis and Intraepidermal Carcinoma Comparing Topical 5-Fluorouracil Combined with 0.0025% Versus 0.005% Calcipotriol and Informing the Design of a Future Definitive Trial
Additional trial identifiers [1] 318343 0
Nil known
Universal Trial Number (UTN)
Trial acronym
REDUCE = Reduction of Excessive Dermal scarring Using 5-Fluorouracil Evaluation
Related trial records

Health condition
Health condition(s) studied:
Actinic Keratosis (AK) 343469 0
Cutaneous Squamous Cell Carcinoma 343470 0
Cutaneous Squamous Cell Carcinoma 343471 0
Condition category
Condition code
Cancer 339570 339570 0 0
Non melanoma skin cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
*Topical fluorouracil 5% combined with calcipotriol 0.005%, applied twice daily to the contralateral side of the face for four days (actinic keratosis) or six days (intraepidermal carcinoma), as tolerated
* dose - small smear; pea sized amount ~ 1-2 ml
*mode of delivery - cream
*adherence - patient diary that includes below:
Date and time of each application (AM/PM)
Side of face treated (A/B)
Confirmation application completed (Yes/No)
Reason for missed dose
Daily inflammatory reaction score (0-10)
Free-text comments
Intervention code [1] 335232 0
Treatment: Drugs
Description of the comparator or control
*Topical fluorouracil 5% combined with calcipotriol 0.0025%, applied twice daily to the contralateral side of the face for four days (actinic keratosis) or six days (intraepidermal carcinoma), as tolerated
* dose - small smear; pea sized amount ~ 1-2 ml
*mode of delivery - cream
*adherence - patient diary that includes below:
Date and time of each application (AM/PM)
Side of face treated (A/B)
Confirmation application completed (Yes/No)
Reason for missed dose
Daily inflammatory reaction score (0-10)
Free-text comments
Within-participant comparison of the alternative concentration applied to the opposite side of the face following random allocation
Control group
Dose comparison

Outcomes
Primary outcome [1] 346749 0
To evaluate the feasibility of delivering a split-face intervention comparing topical 5-fluorouracil combined with 0.0025% and 0.005% calcipotriol in adults with actinic keratosis and intraepidermal carcinoma.
Timepoint [1] 346749 0
Assessment timepoints: 10 days, 3 months, 12 months post treatment commencement.
Primary outcome [2] 346953 0
Recruitment feasibility
Timepoint [2] 346953 0
Assessed throughout recruitment and reported at completion of participant recruitment.
Primary outcome [3] 346954 0
Participant retention and follow-up feasibility
Timepoint [3] 346954 0
Assessed at 3 months and 12 months post-treatment commencement.
Secondary outcome [1] 467313 0
Lesion Clearance
Timepoint [1] 467313 0
At 3 and 12 months post-treatment commencement
Secondary outcome [2] 467314 0
Participant acceptability of treatment
Timepoint [2] 467314 0
Assessed at 3 months and 12 months post-treatment commencement.
Secondary outcome [3] 468310 0
Lesion clearance
Timepoint [3] 468310 0
Assessed at 3 months and 12 months post-treatment commencement.
Secondary outcome [4] 468727 0
Clinician-assessed inflammatory reaction
Timepoint [4] 468727 0
Assessed at 3 months and 12 months post-treatment commencement.
Secondary outcome [5] 468728 0
Clinician-assessed inflammatory reaction
Timepoint [5] 468728 0
Assessed at 3 months and 12 months post-treatment commencement.

Eligibility
Key inclusion criteria
Adults aged 18 to 85 years.

Extensive facial actinic keratoses and/or intraepidermal carcinoma.

Able to comply with treatment requirements.

Able to provide written informed consent.

Willing to attend follow-up visits and clinical photography assessments.

Able to complete study questionnaires.
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Hypersensitivity to fluorouracil.

Known dihydropyrimidine dehydrogenase deficiency.

Pregnancy or breastfeeding.

Recent commencement of retinoids or vitamin B3 therapy.

Other contraindications to topical fluorouracil treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be maintained by the investigational pharmacy, which will prepare and label study medication according to a concealed randomisation schedule. Investigators enrolling participants and participants themselves will not have access to the allocation sequence.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomisation schedule using a 1:1 allocation ratio will be used to randomly assign application of the two study treatments to either the left or right side of the face.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other
Other design features
Split-face (within-participant) randomised trial
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Statistical analyses will account for the paired split-face design. Continuous outcomes will be compared using paired t-tests or Wilcoxon signed-rank tests as appropriate. Binary outcomes will be compared using McNemar's test. Effect estimates and 95% confidence intervals will be reported. As a pilot trial, analyses will focus on estimation of treatment effects and feasibility outcomes to inform the design and sample size of a future definitive study.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 30247 0
Sunshine Coast University Private Hospital - Birtinya
Recruitment postcode(s) [1] 46646 0
4575 - Birtinya

Funding & Sponsors
Funding source category [1] 322898 0
Charities/Societies/Foundations
Name [1] 322898 0
STUDY, EDUCATION AND RESEARCH TRUST FUND (SERTF) SUNSHINE COAST HEALTH
Country [1] 322898 0
Australia
Funding source category [2] 322900 0
Commercial sector/Industry
Name [2] 322900 0
LEO PHARMA
Country [2] 322900 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
STUDY, EDUCATION AND RESEARCH TRUST FUND (SERTF) SUNSHINE COAST HEALTH
Address
Country
Australia
Secondary sponsor category [1] 325827 0
Commercial sector/Industry
Name [1] 325827 0
Leo Pharmacy
Address [1] 325827 0
Country [1] 325827 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321332 0
Griffith University Human Research Ethics Committee
Ethics committee address [1] 321332 0
Ethics committee country [1] 321332 0
Australia
Date submitted for ethics approval [1] 321332 0
16/12/2026
Approval date [1] 321332 0
Ethics approval number [1] 321332 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153390 0
Dr Leith Banney
Address 153390 0
Sunshine Coast Hospital and health service, Queensland Australia, Birtinya, 6 doherty street 4575
Country 153390 0
Australia
Phone 153390 0
+61752022998
Fax 153390 0
Email 153390 0
Contact person for public queries
Name 153391 0
Leith Banney
Address 153391 0
Sunshine Coast hospital and health service, Queensland Australia, Birtinya, 6 doherty street 4575
Country 153391 0
Australia
Phone 153391 0
+61752022998
Fax 153391 0
Email 153391 0
Contact person for scientific queries
Name 153392 0
Leith Banney
Address 153392 0
Sunshine Coast hospital and health service, Queensland Australia, Birtinya, 6 doherty street 4575
Country 153392 0
Australia
Phone 153392 0
+61752022998
Fax 153392 0
Email 153392 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Not approved in PICF



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.